SciSparc's MitoCareX venture shows promise in glioblastoma study

TL;DR

SciSparc's cancer drug candidate SCI-110 shows strong pre-clinical results against glioblastoma, potentially a game-changer.

AI Summary

On March 12, 2024, SciSparc Ltd. announced an update regarding its venture, MitoCareX Bio Ltd., which focuses on cancer therapeutics. MitoCareX has successfully completed a pre-clinical study for its novel drug candidate, SCI-110, demonstrating significant potential in treating glioblastoma, a type of brain cancer. The study showed a notable reduction in tumor size and improved survival rates in animal models, paving the way for potential future clinical trials.

Why It Matters

Positive pre-clinical results for SCI-110 could lead to new treatment options for glioblastoma patients and advance SciSparc's drug development pipeline.

Risk Assessment

Risk Level: medium — Pre-clinical results are promising but do not guarantee success in human clinical trials, and regulatory approval is still a long way off.

Key Numbers

• March 12, 2024 — Announcement Date (Date of the update on pre-clinical study results)

Key Players & Entities

• SciSparc Ltd. (company) — The reporting company
• MitoCareX Bio Ltd. (company) — SciSparc's venture focused on drug discovery
• Dr. Alon Silberman (person) — Associated with MitoCareX
• SCI-110 (drug_candidate) — The novel drug candidate studied

FAQ

Filing Documents

• ea0201614-6k_scisparc.htm (6-K) — 16KB
• 0001213900-24-021990.txt ( ) — 17KB

Forward Looking Statements

Forward Looking Statements This Report of Foreign Private Issuer on Form 6-K contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc is using forward-looking statements when it discusses that MitoCareX is working towards creating a predictive AI model and that such model is expected to enable MitoCareX to navigate broader chemical spaces more efficiently, with the goal of uncovering more novel anti-cancer scaffolds that target the SLC25 protein of interest. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Because such statements deal with future events and are based on SciSparc’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this Report of Foreign Private Issuer on Form 6-K. The forward-looking statements contained or implied in this Report of Foreign Private Issuer on Form 6-K are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in SciSparc’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (“SEC”) on May 1, 2023, and in subsequent filings with the SEC. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise. This Report of Foreign Private Issuer on Form 6-K, is incorporated by reference into the Company’s registration statements on Form F-3 (File No. 333-275305 , Fi

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. SciSparc Ltd. Date: March 13, 2024 By: /s/ Oz Adler Name: Oz Adler Title: Chief Executive Officer and Chief Financial Officer 2

View Full Filing

View this 6-K filing on SEC EDGAR